RecruitingNot ApplicableNCT05490433

Robot-assisted vs. Open Nipple-sparing Mastectomy With Immediate Breast Reconstruction

A Prospective Multicenter Randomized Clinical Trial: Robot-assisted vs. Open Nipple-sparing Mastectomy With Immediate Breast Reconstruction (ROM) Trial


Sponsor

Yonsei University

Enrollment

790 participants

Start Date

Oct 26, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

Research Purpose The present study is designed to generate the strongest evidence available on the role of robotic surgical systems in breast cancer surgery and to elucidate the clinical value of immediate breast reconstruction (IBR) conducted in conjunction with robot-assisted nipple-sparing mastectomy (RNSM). Study Design Overview This study is a prospective, multicenter, randomized clinical trial (ROM Trial) designed to compare the oncologic outcomes of robot-assisted nipple-sparing mastectomy (RNSM) with conventional nipple-sparing mastectomy (CNSM), which includes both traditional and open-chest approaches. Previous retrospective studies of robot-assisted endoscopic surgery have suggested a short learning curve, demonstrating technical feasibility and reproducibility even for less experienced surgeons. However, the absence of rigorously designed randomized clinical trials remains a major global barrier to the broader adoption of robotic breast surgery. In the ROM Trial, eligible patients who provide written informed consent will be randomly assigned in a 1:1 ratio to undergo either RNSM or CNSM. Participants will be blinded to group allocation until the day of surgery (single-blind design). Immediate breast reconstruction (IBR) will be performed in all patients, with the reconstruction method determined in consultation with the breast and/or plastic surgeon following mastectomy.


Eligibility

Sex: FEMALEMin Age: 19 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This study is comparing two approaches to nipple-sparing mastectomy in women with breast cancer: a newer robot-assisted technique versus the standard open surgery. Both are followed by immediate breast reconstruction. Researchers want to know if the robotic approach is as safe and effective as traditional surgery. **You may be eligible if...** - You are a woman aged 19 or older scheduled for mastectomy for breast cancer - Your cancer is clinical stage 0 to IIIA - You want immediate breast reconstruction at the time of mastectomy - You are in good general health **You may NOT be eligible if...** - You are scheduled for breast-conserving surgery (lumpectomy) or are not a candidate for immediate reconstruction - There is evidence that the nipple or skin is directly involved by the cancer - You are pregnant or breastfeeding - You have inflammatory breast cancer, Paget's disease, or cancer limited to lobular carcinoma in situ - You have a large breast size (cup E or larger) - You have a history of previous breast cancer or cancer in the other breast - You have stage IIIB–IV disease Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDURERobot-assisted Nipple-Sparing Mastectomy (RNSM)

Patients undergoing robot-assisted nipple-sparing mastectomy (RNSM) with immediate breast reconstruction (IBR) will be enrolled in this group. RNSM will be performed using robotic surgical platforms, including the da Vinci S, Si, X, Xi, and SP systems. The procedure will be conducted through an axillary or lateral chest wall incision. During surgery, posterior areolar tissue sampling for frozen section biopsy will be recommended. If suspicious lesions are detected at the superficial or posterior margins, frozen section biopsy of those lesions will also be performed. When tumor involvement of the nipple-areola complex (NAC), superficial margin, or posterior margin is confirmed by frozen section biopsy, additional resection including the skin and NAC, or postoperative radiotherapy, will be considered.

PROCEDUREConventional nipple sparing mastectomy(CNSM)

Patients who undergo conventional nipple-sparing mastectomy (CNSM) with immediate breast reconstruction (IBR) will be enrolled in this group. CNSM is performed without the use of robotic or endoscopic surgical systems, and all types of skin incisions are permitted. During surgery, posterior areolar tissue sampling for frozen section biopsy is recommended. If suspicious lesions suggesting tumor involvement are identified at the superficial or posterior margins, frozen section biopsy should also be performed. When frozen section biopsy confirms tumor involvement of the nipple-areola complex (NAC), superficial margin, or posterior margin, additional excision including the skin and NAC, or postoperative radiotherapy, will be considered.


Locations(17)

Samsung Changwon Medical Center

Changwon, South Korea

Keimyung University Dongsan Hospital

Daegu, South Korea

Kyungpook National University Chilgok Hospital

Daegu, South Korea

Yeungnam University Medical Center

Daegu, South Korea

Myongji Hospital

Goyang-si, South Korea

The Catholic University of Korea, Incheon ST. Mary's Hospital

Incheon, South Korea

Kosin University Gospel Hospital

Pusan, South Korea

Chungnam National University Sejong Hospital

Sejong, South Korea

Asan Medical Center

Seoul, South Korea

Gangnam Severance Hospital

Seoul, South Korea

Korea University Anam Hospital

Seoul, South Korea

Korea University Ansan Hospital

Seoul, South Korea

Samsung Medical Center

Seoul, South Korea

Seoul National University Hospital

Seoul, South Korea

Soonchunhyang University Hospital Seoul

Seoul, South Korea

Yonsei University Health System, Severance Hospital

Seoul, South Korea

Yongin Severance Hospital

Yongin-si, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05490433